Citius Pharmaceuticals (CTXR) Short Interest Ratio & Short Volume $0.72 -0.04 (-5.62%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.03 (+4.57%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Citius Pharmaceuticals Short Interest DataCitius Pharmaceuticals (CTXR) has a short interest of 755,900 shares, representing 8.57% of the float (the number of shares available for trading by the public). This marks a 10.97% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.6, indicating that it would take 2.6 days of the average trading volume of 183,736 shares to cover all short positions.Current Short Interest755,900 sharesPrevious Short Interest681,200 sharesChange Vs. Previous Month+10.97%Dollar Volume Sold Short$755,900.00Short Interest Ratio2.6 Days to CoverLast Record DateApril 15, 2025Outstanding Shares8,895,000 sharesFloat Size8,820,000 sharesShort Percent of Float8.57%Today's Trading Volume130,847 sharesAverage Trading Volume183,736 sharesToday's Volume Vs. Average71% Short Selling Citius Pharmaceuticals? Sign up to receive the latest short interest report for Citius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCTXR Short Interest Over TimeCTXR Days to Cover Over TimeCTXR Percentage of Float Shorted Over Time Citius Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2025755,900 shares $755,900.00 +11.0%8.6%2.6 $1.00 3/31/2025681,200 shares $1.01 million +31.6%7.7%2.3 $1.49 3/15/2025517,600 shares $776,400.00 -5.4%6.4%3.7 $1.50 2/28/2025547,000 shares $902,550.00 +1.3%6.8%3.6 $1.65 2/15/2025540,100 shares $1.45 million +5.1%6.7%1.8 $2.69 1/31/2025513,900 shares $1.38 million -12.5%6.4%1.8 $2.69 1/15/2025587,000 shares $2.00 million -1.4%7.3%2.2 $3.40 12/31/2024595,300 shares $2.38 million +13.6%7.5%2.3 $4.00 12/15/2024523,900 shares $1.46 million -13.2%7.3%2.3 $2.79 11/30/2024603,700 shares $2.00 million +12.2%8.4%2.8 $3.32 Get the Latest News and Ratings for CTXR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024537,900 shares $2.69 million -95.4%7.5%2.8 $5.00 10/31/202411,790,000 shares $4.39 million -5.1%N/A10.5 $0.37 10/15/202412,420,000 shares $4.65 million -2.7%N/A8.9 $0.37 9/30/202412,770,000 shares $6.39 million +1.9%N/A7.2 $0.50 9/15/202412,530,000 shares $6.51 million -6.4%N/A5.8 $0.52 8/31/202413,390,000 shares $7.63 million +9.0%N/A6.3 $0.57 8/15/202412,280,000 shares $7.20 million -16.1%N/A5.5 $0.59 7/31/202414,630,000 shares $13.24 million +21.9%N/A5.8 $0.91 7/15/202412,000,000 shares $9.18 million -15.2%N/A5.4 $0.77 6/30/202414,150,000 shares $8.26 million -8.5%N/A7.1 $0.58 6/15/202415,460,000 shares $9.67 million -2.8%N/A9.9 $0.63 5/31/202415,910,000 shares $11.10 million +9.9%N/A10.6 $0.70 5/15/202414,480,000 shares $9.05 million +0.4%N/A10.5 $0.62 4/30/202414,430,000 shares $10.77 million +9.4%N/A15.6 $0.75 4/15/202413,190,000 shares $10.09 million +6.1%N/A15.5 $0.77 3/31/202412,430,000 shares $11.15 million +2.1%N/A16.9 $0.90 3/15/202412,180,000 shares $8.97 million +2.7%N/A18.6 $0.74 2/29/202411,860,000 shares $9.11 million +2.4%N/A18.9 $0.77 2/15/202411,580,000 shares $9.75 million -0.3%N/A18.5 $0.84 1/31/202411,610,000 shares $7.21 million -16.7%N/A20.2 $0.62 1/15/202413,940,000 shares $10.46 million -4.7%N/A23.6 $0.75 12/31/202314,620,000 shares $11.06 million +8.6%N/A26.2 $0.76 12/15/202313,460,000 shares $10.73 million -15.0%N/A25.1 $0.80 11/30/202315,830,000 shares $12.20 million -1.3%N/A25.1 $0.77 11/15/202316,030,000 shares $12.31 million -5.1%N/A25.1 $0.77 10/31/202316,890,000 shares $12.71 million -1.9%N/A23.3 $0.75 10/15/202317,210,000 shares $12.00 million -7.2%N/A17.3 $0.70 9/30/202318,540,000 shares $12.69 million -4.5%N/A18 $0.68 9/15/202319,420,000 shares $14.74 million -1.1%N/A15.9 $0.76 8/31/202319,640,000 shares $17.92 million -1.1%N/A13.3 $0.91Watch This Robotics Demo Before July 23rd (Ad)Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." Click here to watch the demo… 8/15/202319,850,000 shares $17.10 million -4.6%N/A12.7 $0.86 7/31/202320,800,000 shares $20.59 million +2.0%N/A10.8 $0.99 7/15/202320,390,000 shares $24.26 million +8.7%N/A11 $1.19 6/30/202318,760,000 shares $22.51 million +27.9%N/A9.9 $1.20 6/15/202314,670,000 shares $18.48 million +6.6%N/A8.2 $1.26 5/31/202313,760,000 shares $15.96 million +13.4%N/A9.5 $1.16 5/15/202312,130,000 shares $15.53 million -10.8%N/A8.9 $1.28 4/30/202313,600,000 shares $19.72 million +6.7%N/A14.3 $1.45 4/15/202312,750,000 shares $20.91 million +6.5%9.5%14 $1.64 3/31/202311,970,000 shares $14.00 million +4.5%8.9%13.5 $1.17 3/15/202311,450,000 shares $11.79 million +1.5%8.6%13.1 $1.03 2/28/202311,280,000 shares $12.97 million +2.8%8.4%13.6 $1.15 2/15/202310,970,000 shares $13.49 million -5.4%8.2%13.5 $1.23 1/31/202311,600,000 shares $16.12 million +6.6%8.7%14.9 $1.39 1/15/202310,880,000 shares $12.19 million -0.7%8.1%15.3 $1.12 12/30/202210,960,000 shares $8.66 million -3.4%8.2%22 $0.79 12/15/202211,340,000 shares $12.81 million -0.4%N/A23.1 $1.13 11/30/202211,390,000 shares $13.33 million +4.5%N/A23.2 $1.17 11/15/202210,900,000 shares $11.66 million +1.3%N/A22.2 $1.07 10/31/202210,760,000 shares $11.62 million -3.0%N/A19.2 $1.08 10/15/202211,090,000 shares $11.98 million -0.1%N/A19.5 $1.08 9/30/202211,100,000 shares $13.43 million +6.3%N/A17.8 $1.21 9/15/202210,440,000 shares $12.84 million +3.6%N/A12.7 $1.23 8/31/202210,080,000 shares $12.40 million +2.0%N/A11.1 $1.23 8/15/20229,880,000 shares $12.55 million -0.7%N/A9.1 $1.27 7/31/20229,950,000 shares $8.89 million -4.8%N/A7.8 $0.89 7/15/202210,450,000 shares $9.54 million +1.1%N/A6.6 $0.91 6/30/202210,340,000 shares $9.51 million -29.1%N/A5.2 $0.92 6/15/202214,590,000 shares $13.92 million -2.7%N/A7.1 $0.95 5/31/202214,990,000 shares $14.09 million +7.2%11.2%7.9 $0.94 5/15/202213,990,000 shares $12.52 million +5.7%10.5%7.6 $0.90 4/30/202213,230,000 shares $13.36 million +25.1%9.9%7.1 $1.01 4/15/202210,580,000 shares $16.40 million +13.6%7.9%6.3 $1.55 3/31/20229,310,000 shares $16.66 million +2.4%7.0%6.2 $1.79 3/15/20229,090,000 shares $14.36 million +1.8%6.8%6.9 $1.58 2/28/20228,930,000 shares $13.75 million -11.2%6.7%6.2 $1.54 2/15/202210,060,000 shares $16.40 million -6.1%7.5%6.5 $1.63 1/31/202210,710,000 shares $16.17 million -5.3%8.0%6.7 $1.51 1/15/202211,310,000 shares $17.30 million -7.0%8.5%6.7 $1.53 12/31/202112,160,000 shares $18.73 million -7.3%9.1%6.6 $1.54 12/15/202113,110,000 shares $22.29 million +2.5%9.8%6.7 $1.70 11/30/202112,790,000 shares $21.62 million -5.0%9.6%6.2 $1.69 11/15/202113,460,000 shares $24.36 million -7.0%10.1%5.6 $1.81 10/29/202114,470,000 shares $27.06 million +2.1%10.8%5.9 $1.87 10/15/202114,170,000 shares $29.62 million -2.0%10.6%5.3 $2.09 9/30/202114,460,000 shares $29.35 million +0.4%10.8%4.9 $2.03 9/15/202114,410,000 shares $29.25 million +11.2%10.8%2.6 $2.03 8/31/202112,960,000 shares $29.16 million -5.4%9.8%1.6 $2.25 8/13/202113,700,000 shares $24.80 million -6.0%10.3%1.6 $1.81 7/30/202114,570,000 shares $27.54 million -13.9%11.8%1.7 $1.89Watch This Robotics Demo Before July 23rd (Ad)Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." Click here to watch the demo… 7/15/202116,920,000 shares $32.49 million -20.9%13.7%1.7 $1.92 6/30/202121,400,000 shares $74.47 million +40.4%17.4%2.1 $3.48 6/15/202115,240,000 shares $49.23 million -3.7%12.4%2 $3.23 5/28/202115,820,000 shares $36.07 million +8.6%12.9%2.5 $2.28 5/14/202114,570,000 shares $27.54 million +24.3%N/A1.7 $1.89 4/30/202111,720,000 shares $24.73 million -10.4%N/A0.8 $2.11 4/15/202113,080,000 shares $23.54 million +18.6%N/A0.9 $1.80 3/31/202111,030,000 shares $20.41 million +51.3%N/A0.8 $1.85 3/15/20217,290,000 shares $13.92 million -27.9%N/A0.6 $1.91 2/26/202110,110,000 shares $20.83 million +261.1%N/A0.9 $2.06 2/12/20212,800,000 shares $3.81 million +15.7%N/A0.3 $1.36 1/29/20212,420,000 shares $2.90 million +112.3%N/A1.6 $1.20 1/15/20211,140,000 shares $1.30 million -9.5%N/A1.4 $1.14 12/31/20201,260,000 shares $1.31 million -23.6%N/A1.8 $1.04 12/15/20201,650,000 shares $1.77 million +71.8%N/A2.2 $1.07 11/30/2020960,600 shares $947,824.02 -20.0%N/A1.2 $0.99 11/15/20201,200,000 shares $1.15 million -9.1%N/A1.6 $0.95 10/30/20201,320,000 shares $1.33 million +6.5%N/A1.6 $1.01 10/15/20201,240,000 shares $1.33 million +53.3%N/A1.1 $1.07 9/30/2020809,100 shares $841,464.00 +15.4%N/A0.6 $1.04 9/15/2020701,200 shares $743,272.00 -8.9%N/A0.2 $1.06 8/31/2020769,400 shares $715,542.00 +4.6%N/A0.3 $0.93 8/14/2020735,600 shares $787,092.00 -59.8%N/A0.2 $1.07 7/31/20201,830,000 shares $2.36 million +28.0%N/A0.5 $1.29 7/15/20201,430,000 shares $1.70 million -56.1%N/A0.4 $1.19 6/30/20203,260,000 shares $3.68 million +242.3%N/A1.1 $1.13 6/15/2020952,300 shares $842,595.04 +10.0%N/A0.6 $0.88 5/29/2020865,500 shares $751,254.00 -33.4%N/A0.6 $0.87 5/15/20201,300,000 shares $1.05 million +9.2%N/A1.1 $0.81 CTXR Short Interest - Frequently Asked Questions What is Citius Pharmaceuticals' current short interest? Short interest is the volume of Citius Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 755,900 shares of CTXR short. 8.57% of Citius Pharmaceuticals' shares are currently sold short. Learn More on Citius Pharmaceuticals' current short interest. What is a good short interest ratio for Citius Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CTXR shares currently have a short interest ratio of 3.0. Learn More on Citius Pharmaceuticals's short interest ratio. Which institutional investors are shorting Citius Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Citius Pharmaceuticals: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Citius Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.57% of Citius Pharmaceuticals' floating shares are currently sold short. Is Citius Pharmaceuticals' short interest increasing or decreasing? Citius Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 755,900 shares, an increase of 11.0% from the previous total of 681,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Citius Pharmaceuticals' float size? Citius Pharmaceuticals currently has issued a total of 8,895,000 shares. Some of Citius Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Citius Pharmaceuticals currently has a public float of 8,820,000 shares. How does Citius Pharmaceuticals' short interest compare to its competitors? 8.57% of Citius Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Citius Pharmaceuticals: Alterity Therapeutics Limited (0.39%), Cadrenal Therapeutics, Inc. (2.45%), Pluri Inc. (0.24%), Marinus Pharmaceuticals, Inc. (3.95%), Kezar Life Sciences, Inc. (1.09%), ALX Oncology Holdings Inc. (18.06%), Estrella Immunopharma, Inc. (0.02%), Allakos Inc. (1.36%), FibroGen, Inc. (4.23%), MiNK Therapeutics, Inc. (2.65%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Citius Pharmaceuticals stock? Short selling CTXR is an investing strategy that aims to generate trading profit from Citius Pharmaceuticals as its price is falling. CTXR shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Citius Pharmaceuticals? A short squeeze for Citius Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CTXR, which in turn drives the price of the stock up even further. How often is Citius Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTXR, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Alterity Therapeutics Short Interest Data Cadrenal Therapeutics Short Interest Data Pluri Short Interest Data Marinus Pharmaceuticals Short Interest Data Kezar Life Sciences Short Interest Data ALX Oncology Short Interest Data Estrella Immunopharma Short Interest Data Allakos Short Interest Data FibroGen Short Interest Data MiNK Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CTXR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTXR Stock Free CTXR Stock Alerts